Dual‐Targeting, Hybrid Antifungal Agents Targeting Candida albicans —An Overview
Abstract
Due to environmental degradation, substance abuse, and immunological loss, fungal diseases are rising. Candida sp. can inflame tissues and organs. In addition, fungi enter deep tissues to generate invasive fungal infections (IFIs), a long-term worldwide health risk, especially for HIV/chemotherapy patients with compromised immune systems. The present treatment uses single-target antifungals like azoles, allylamines, and pyrimidines. But drug-resistant fungi and widespread adverse effects have limited their therapeutic efficacy. Thus, innovative, safe, and effective antifungals are needed. Through the 20th century, the pharmaceutical industry adopted the "one molecule, one target, one disease" mentality which led to various effective selective drugs that will dominate disease treatment. But, unfortunately, even with the best research, targeting one target may not work in complicated illnesses. Thus, drugs that activate several targets simultaneously, to improve efficacy and safety, are gaining interest. Multitarget medicines involve monotherapies, medication cocktails, and combination drugs. The second method, multitarget-directed ligands (MTDLs), uses one active component that treats multifactorial diseases. In MTDL, new chemical entities (NCEs) are created which may solve various issues related to combination therapies, including: (1) establishing balanced and multi-selective potency across targets, (2) matching PK/PD properties for components, (3) better patient…
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.